JP2011098896A - Composition for reducing uric acid value - Google Patents
Composition for reducing uric acid value Download PDFInfo
- Publication number
- JP2011098896A JP2011098896A JP2009253183A JP2009253183A JP2011098896A JP 2011098896 A JP2011098896 A JP 2011098896A JP 2009253183 A JP2009253183 A JP 2009253183A JP 2009253183 A JP2009253183 A JP 2009253183A JP 2011098896 A JP2011098896 A JP 2011098896A
- Authority
- JP
- Japan
- Prior art keywords
- acid
- food
- uric acid
- composition
- composition according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 title claims abstract description 66
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 title claims abstract description 66
- 229940116269 uric acid Drugs 0.000 title claims abstract description 66
- 239000000203 mixture Substances 0.000 title claims abstract description 47
- PXQPEWDEAKTCGB-UHFFFAOYSA-N orotic acid Chemical compound OC(=O)C1=CC(=O)NC(=O)N1 PXQPEWDEAKTCGB-UHFFFAOYSA-N 0.000 claims abstract description 124
- 229960005010 orotic acid Drugs 0.000 claims abstract description 61
- 235000013305 food Nutrition 0.000 claims abstract description 44
- 150000003839 salts Chemical class 0.000 claims abstract description 36
- 229940024606 amino acid Drugs 0.000 claims abstract description 35
- 235000001014 amino acid Nutrition 0.000 claims abstract description 35
- 150000001413 amino acids Chemical class 0.000 claims abstract description 35
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 claims abstract description 18
- 201000005569 Gout Diseases 0.000 claims abstract description 18
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims abstract description 17
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims abstract description 17
- 239000004480 active ingredient Substances 0.000 claims abstract description 16
- 235000013922 glutamic acid Nutrition 0.000 claims abstract description 16
- 239000004220 glutamic acid Substances 0.000 claims abstract description 16
- 201000001431 Hyperuricemia Diseases 0.000 claims abstract description 15
- 229960001230 asparagine Drugs 0.000 claims abstract description 14
- 235000009582 asparagine Nutrition 0.000 claims abstract description 14
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 claims abstract description 12
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 claims abstract description 11
- 235000004554 glutamine Nutrition 0.000 claims abstract description 11
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 claims abstract description 10
- 235000013376 functional food Nutrition 0.000 claims abstract description 6
- 230000036541 health Effects 0.000 claims abstract description 6
- 230000001575 pathological effect Effects 0.000 claims abstract description 6
- 210000003734 kidney Anatomy 0.000 claims abstract description 5
- 206010030113 Oedema Diseases 0.000 claims abstract description 4
- 208000001647 Renal Insufficiency Diseases 0.000 claims abstract description 4
- 235000015872 dietary supplement Nutrition 0.000 claims abstract description 4
- 201000006370 kidney failure Diseases 0.000 claims abstract description 4
- 206010054107 Nodule Diseases 0.000 claims abstract description 3
- 235000013361 beverage Nutrition 0.000 claims description 13
- 201000010099 disease Diseases 0.000 claims description 12
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 12
- 238000004519 manufacturing process Methods 0.000 claims description 10
- 235000013402 health food Nutrition 0.000 claims description 7
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 5
- 229940127557 pharmaceutical product Drugs 0.000 claims description 5
- 230000002265 prevention Effects 0.000 claims description 4
- 206010007027 Calculus urinary Diseases 0.000 claims description 3
- 208000008281 urolithiasis Diseases 0.000 claims description 2
- 210000002307 prostate Anatomy 0.000 claims 1
- 230000009471 action Effects 0.000 abstract description 10
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 abstract description 3
- 208000004403 Prostatic Hyperplasia Diseases 0.000 abstract description 3
- 208000009911 Urinary Calculi Diseases 0.000 abstract description 3
- 201000004240 prostatic hypertrophy Diseases 0.000 abstract description 3
- POJWUDADGALRAB-UHFFFAOYSA-N allantoin Chemical compound NC(=O)NC1NC(=O)NC1=O POJWUDADGALRAB-UHFFFAOYSA-N 0.000 description 22
- 239000003814 drug Substances 0.000 description 18
- 210000004369 blood Anatomy 0.000 description 15
- 239000008280 blood Substances 0.000 description 15
- -1 inorganic acid salts Chemical class 0.000 description 13
- POJWUDADGALRAB-PVQJCKRUSA-N Allantoin Natural products NC(=O)N[C@@H]1NC(=O)NC1=O POJWUDADGALRAB-PVQJCKRUSA-N 0.000 description 11
- 229960000458 allantoin Drugs 0.000 description 11
- 230000000694 effects Effects 0.000 description 11
- 244000269722 Thea sinensis Species 0.000 description 10
- 235000013616 tea Nutrition 0.000 description 10
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 8
- 235000003704 aspartic acid Nutrition 0.000 description 7
- 229960005261 aspartic acid Drugs 0.000 description 7
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 7
- 235000013336 milk Nutrition 0.000 description 7
- 239000008267 milk Substances 0.000 description 7
- 210000004080 milk Anatomy 0.000 description 7
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 235000009508 confectionery Nutrition 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 235000013618 yogurt Nutrition 0.000 description 6
- 230000003247 decreasing effect Effects 0.000 description 5
- 239000003755 preservative agent Substances 0.000 description 5
- 230000002829 reductive effect Effects 0.000 description 5
- 238000003786 synthesis reaction Methods 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 4
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical class NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
- 241000700159 Rattus Species 0.000 description 4
- 235000013405 beer Nutrition 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 239000003381 stabilizer Substances 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 239000011230 binding agent Substances 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 239000007884 disintegrant Substances 0.000 description 3
- 239000002270 dispersing agent Substances 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000003925 fat Substances 0.000 description 3
- 235000019197 fats Nutrition 0.000 description 3
- 235000019225 fermented tea Nutrition 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 229910052500 inorganic mineral Inorganic materials 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 244000005700 microbiome Species 0.000 description 3
- 235000020124 milk-based beverage Nutrition 0.000 description 3
- 235000010755 mineral Nutrition 0.000 description 3
- 239000011707 mineral Substances 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 239000002719 pyrimidine nucleotide Substances 0.000 description 3
- 150000003230 pyrimidines Chemical class 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 235000000346 sugar Nutrition 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 2
- 239000004278 EU approved seasoning Substances 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical class NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 2
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical class OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Chemical class NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 2
- 239000004472 Lysine Chemical class 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical class C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical class C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 235000006468 Thea sinensis Nutrition 0.000 description 2
- 239000005862 Whey Substances 0.000 description 2
- 102000007544 Whey Proteins Human genes 0.000 description 2
- 108010046377 Whey Proteins Proteins 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- 230000006229 amino acid addition Effects 0.000 description 2
- 150000003863 ammonium salts Chemical class 0.000 description 2
- 235000014171 carbonated beverage Nutrition 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 2
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 2
- 229940105329 carboxymethylcellulose Drugs 0.000 description 2
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 235000013365 dairy product Nutrition 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 230000029142 excretion Effects 0.000 description 2
- 235000021107 fermented food Nutrition 0.000 description 2
- 238000005187 foaming Methods 0.000 description 2
- 235000011194 food seasoning agent Nutrition 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 235000009569 green tea Nutrition 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 235000018977 lysine Nutrition 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- BJEPYKJPYRNKOW-UHFFFAOYSA-N malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 2
- 239000002207 metabolite Substances 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Chemical class 0.000 description 2
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Chemical class OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 2
- 235000008729 phenylalanine Nutrition 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
- 150000003212 purines Chemical class 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 235000015067 sauces Nutrition 0.000 description 2
- 235000014214 soft drink Nutrition 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 150000008163 sugars Chemical class 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- KPGXRSRHYNQIFN-UHFFFAOYSA-N 2-oxoglutaric acid Chemical compound OC(=O)CCC(=O)C(O)=O KPGXRSRHYNQIFN-UHFFFAOYSA-N 0.000 description 1
- PQGCEDQWHSBAJP-TXICZTDVSA-N 5-O-phosphono-alpha-D-ribofuranosyl diphosphate Chemical compound O[C@H]1[C@@H](O)[C@@H](O[P@](O)(=O)OP(O)(O)=O)O[C@@H]1COP(O)(O)=O PQGCEDQWHSBAJP-TXICZTDVSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 229920002126 Acrylic acid copolymer Polymers 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 240000006439 Aspergillus oryzae Species 0.000 description 1
- 235000002247 Aspergillus oryzae Nutrition 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 240000001548 Camellia japonica Species 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 244000302899 Cassia mimosoides Species 0.000 description 1
- 235000014112 Cassia mimosoides Nutrition 0.000 description 1
- 235000009024 Ceanothus sanguineus Nutrition 0.000 description 1
- 229920000623 Cellulose acetate phthalate Polymers 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- 229920003134 Eudragit® polymer Polymers 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 240000005979 Hordeum vulgare Species 0.000 description 1
- 235000007340 Hordeum vulgare Nutrition 0.000 description 1
- 102000008100 Human Serum Albumin Human genes 0.000 description 1
- 108091006905 Human Serum Albumin Proteins 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 235000010254 Jasminum officinale Nutrition 0.000 description 1
- 240000005385 Jasminum sambac Species 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 240000003553 Leptospermum scoparium Species 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 206010067125 Liver injury Diseases 0.000 description 1
- 235000015459 Lycium barbarum Nutrition 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 208000001145 Metabolic Syndrome Diseases 0.000 description 1
- CERQOIWHTDAKMF-UHFFFAOYSA-N Methacrylic acid Chemical compound CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 description 1
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 1
- 229920000881 Modified starch Polymers 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- 206010029148 Nephrolithiasis Diseases 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- HCBIBCJNVBAKAB-UHFFFAOYSA-N Procaine hydrochloride Chemical compound Cl.CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 HCBIBCJNVBAKAB-UHFFFAOYSA-N 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- ABBQHOQBGMUPJH-UHFFFAOYSA-M Sodium salicylate Chemical compound [Na+].OC1=CC=CC=C1C([O-])=O ABBQHOQBGMUPJH-UHFFFAOYSA-M 0.000 description 1
- 244000228451 Stevia rebaudiana Species 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 208000006568 Urinary Bladder Calculi Diseases 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- 108010093894 Xanthine oxidase Proteins 0.000 description 1
- 102100033220 Xanthine oxidase Human genes 0.000 description 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- OFCNXPDARWKPPY-UHFFFAOYSA-N allopurinol Chemical compound OC1=NC=NC2=C1C=NN2 OFCNXPDARWKPPY-UHFFFAOYSA-N 0.000 description 1
- 229960003459 allopurinol Drugs 0.000 description 1
- AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical class [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 235000009697 arginine Nutrition 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- WHQCHUCQKNIQEC-UHFFFAOYSA-N benzbromarone Chemical compound CCC=1OC2=CC=CC=C2C=1C(=O)C1=CC(Br)=C(O)C(Br)=C1 WHQCHUCQKNIQEC-UHFFFAOYSA-N 0.000 description 1
- 229960002529 benzbromarone Drugs 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000000090 biomarker Substances 0.000 description 1
- 235000020279 black tea Nutrition 0.000 description 1
- 230000036765 blood level Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 235000014121 butter Nutrition 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 229940041514 candida albicans extract Drugs 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 229940084030 carboxymethylcellulose calcium Drugs 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229940081734 cellulose acetate phthalate Drugs 0.000 description 1
- 235000013339 cereals Nutrition 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- 239000007910 chewable tablet Substances 0.000 description 1
- 229960004926 chlorobutanol Drugs 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 235000016213 coffee Nutrition 0.000 description 1
- 235000013353 coffee beverage Nutrition 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 235000018597 common camellia Nutrition 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 238000000748 compression moulding Methods 0.000 description 1
- 235000008504 concentrate Nutrition 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 235000014510 cooky Nutrition 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 235000015140 cultured milk Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 238000002224 dissection Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 235000019541 flavored milk drink Nutrition 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 235000015203 fruit juice Nutrition 0.000 description 1
- 239000000417 fungicide Substances 0.000 description 1
- 239000003349 gelling agent Substances 0.000 description 1
- 229940050410 gluconate Drugs 0.000 description 1
- 229960002989 glutamic acid Drugs 0.000 description 1
- 229960002743 glutamine Drugs 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 235000015220 hamburgers Nutrition 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 231100000234 hepatic damage Toxicity 0.000 description 1
- 235000015092 herbal tea Nutrition 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 229920003063 hydroxymethyl cellulose Polymers 0.000 description 1
- 229940031574 hydroxymethyl cellulose Drugs 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 229920003132 hydroxypropyl methylcellulose phthalate Polymers 0.000 description 1
- 229940031704 hydroxypropyl methylcellulose phthalate Drugs 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 229960004903 invert sugar Drugs 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- 239000008274 jelly Substances 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 230000008818 liver damage Effects 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 229940049920 malate Drugs 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 235000013310 margarine Nutrition 0.000 description 1
- 239000003264 margarine Substances 0.000 description 1
- 230000000873 masking effect Effects 0.000 description 1
- 239000008268 mayonnaise Substances 0.000 description 1
- 235000010746 mayonnaise Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229920003145 methacrylic acid copolymer Polymers 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 235000020925 non fasting Nutrition 0.000 description 1
- 235000012149 noodles Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- WWZKQHOCKIZLMA-UHFFFAOYSA-M octanoate Chemical compound CCCCCCCC([O-])=O WWZKQHOCKIZLMA-UHFFFAOYSA-M 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 235000020333 oolong tea Nutrition 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 235000015927 pasta Nutrition 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 229960003742 phenol Drugs 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229940093429 polyethylene glycol 6000 Drugs 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
- 235000008476 powdered milk Nutrition 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 229960001309 procaine hydrochloride Drugs 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 235000011962 puddings Nutrition 0.000 description 1
- 239000002213 purine nucleotide Substances 0.000 description 1
- 235000020185 raw untreated milk Nutrition 0.000 description 1
- 230000009103 reabsorption Effects 0.000 description 1
- 230000000384 rearing effect Effects 0.000 description 1
- HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 description 1
- 229940100618 rectal suppository Drugs 0.000 description 1
- 239000006215 rectal suppository Substances 0.000 description 1
- 235000021067 refined food Nutrition 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 235000013580 sausages Nutrition 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 229960004025 sodium salicylate Drugs 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000013599 spices Nutrition 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000007940 sugar coated tablet Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 239000012085 test solution Substances 0.000 description 1
- QEMXHQIAXOOASZ-UHFFFAOYSA-N tetramethylammonium Chemical compound C[N+](C)(C)C QEMXHQIAXOOASZ-UHFFFAOYSA-N 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 239000006216 vaginal suppository Substances 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 208000019553 vascular disease Diseases 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 238000009423 ventilation Methods 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 239000008256 whipped cream Substances 0.000 description 1
- 239000012138 yeast extract Substances 0.000 description 1
- 150000003751 zinc Chemical class 0.000 description 1
Images
Landscapes
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Non-Alcoholic Beverages (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
【課題】優れた尿酸値低下作用を発揮し、痛風、高尿酸血症、痛風結節、尿路結石、腎不全、痛風腎、前立腺肥大、および浮腫などの病態の改善ができる、医薬品や健康食品、機能性食品、特定保健用食品、栄養補助食品、または病者用食品などで使用する組成物の提供。
【解決手段】オロト酸またはその塩、並びにアスパラギン、グルタミン、およびグルタミン酸からなる群より選ばれる少なくとも１種であるアミノ酸とを有効成分として含有する尿酸値低下用組成物。
【選択図】なし[PROBLEMS] To provide an excellent uric acid level lowering action, and can improve the pathological conditions such as gout, hyperuricemia, gout nodules, urinary calculi, renal failure, gout kidney, prostatic hypertrophy, and edema. Providing compositions for use in functional foods, foods for specified health use, dietary supplements, foods for sick people, etc.
A composition for lowering uric acid level, containing orotic acid or a salt thereof and at least one amino acid selected from the group consisting of asparagine, glutamine, and glutamic acid as active ingredients.
[Selection figure] None
Description
本発明は、尿酸値低下用組成物、より詳しくは、オロト酸またはその塩、およびアミノ酸を有効成分として含有する、尿酸値低下用組成物に関する。 The present invention relates to a composition for lowering uric acid levels, and more particularly to a composition for lowering uric acid levels, containing orotic acid or a salt thereof and an amino acid as active ingredients.
尿酸は、ヒトにおいてプリン体の最終代謝産物として存在する。尿酸の排泄能の低下や産生の過剰等の要因により、血中の尿酸値が７ｍｇ／ｄｌ以上になると、高尿酸血症と定義される。高尿酸血症発症者は増加しており、日本国内に９００万人程度いると言われている。 Uric acid exists as a final metabolite of purines in humans. Hyperuricemia is defined when the uric acid level in the blood is 7 mg / dl or more due to factors such as reduced uric acid excretion and excessive production. The number of hyperuricemia patients is increasing, and it is said that there are about 9 million people in Japan.
高尿酸血症状態が慢性化すると、痛風関節炎、尿路結石、痛風腎等の病状を発症する危険性が高まる。また、近年の疫学研究により、高尿酸血症は、心・脳血管障害の独立した危険因子であることが示唆されてきており、メタボリックシンドロームのバイオマーカーとしての重要性が指摘されてきている。以上のことから、血中尿酸値を適正にコントロールすることは、これら疾患を予防する観点から重要となり、高尿酸血症を改善する医薬品や食品が強く望まれている。 When the hyperuricemia state becomes chronic, the risk of developing medical conditions such as gout arthritis, urinary calculus, gout kidney and the like increases. Recent epidemiological studies have suggested that hyperuricemia is an independent risk factor for cardio-cerebral vascular disorders, and the importance of metabolic syndrome as a biomarker has been pointed out. From the above, it is important to appropriately control the blood uric acid level from the viewpoint of preventing these diseases, and pharmaceuticals and foods that improve hyperuricemia are strongly desired.
これまでに、尿酸値低下用薬組成物として、尿酸産生抑制組成物のアロプリノールや尿酸排泄促進組成物のベンズブロマロン等が提供されている。しかし、これらの薬剤組成物は、効果がある半面、肝障害等の副作用を伴うことが多い。また、高尿酸血症を改善する食品素材も報告されているが、これらは全て、キサンチンオキシダーゼ阻害による尿酸産生抑制の機序によるものであり（特許文献１〜３等）、排泄低下型の高尿酸血症を改善する食品素材については開示されていない。 So far, uric acid production-suppressing compositions, allopurinol, uric acid excretion promoting compositions, benzbromarone, and the like have been provided as pharmaceutical compositions for lowering uric acid levels. However, these pharmaceutical compositions are effective, but often have side effects such as liver damage. In addition, food materials that improve hyperuricemia have also been reported, but these are all due to the mechanism of suppression of uric acid production by inhibiting xanthine oxidase (Patent Documents 1 to 3, etc.) No food material that improves uricemia is disclosed.
オロト酸は、ピリミジンヌクレオチド合成の前駆物質であり、牛乳、粉ミルク、ホエー等の乳製品中に存在する。オロト酸は、日本国内では、滋養強壮、肝機能促進、および肌荒れ改善等を目的とする第２類医薬品、第３類医薬品、および医薬部外品に使用されている。また、海外では、医薬品や健康食品として使用されている。オロト酸により尿酸値が低下することは既に報告されており、１g、２８日間のオロト酸摂取により、尿酸値が約０．６ｍｇ／ｄｌ有意に低下したという報告がある（非特許文献１）。また、６g、１週間のオロト酸摂取により、尿中尿酸の排泄量が有意に増加すること（非特許文献２）、及び、オロト酸は腎臓の尿酸トランスポーターＵＲＡＴ−１を競合的に阻害すること（非特許文献３）から、オロト酸は尿酸の再吸収を阻害し、尿酸値を低下させることが示唆される。更に、オロト酸を摂取すると、肝臓中の５−ホスホリボシル１−ピロリン酸（ＰＲＰＰ）を消費し、ピリミジンヌクレオチド合成が亢進することから、プリンの新規合成が抑制され、尿酸へ異化される量が減少し、尿酸値が低下することが考えられる。
Orotic acid is a precursor of pyrimidine nucleotide synthesis and is present in dairy products such as milk, powdered milk and whey. In Japan, orotic acid is used in
一方、アスパラギン酸やグルタミン等の一部のアミノ酸は、プリン及びピリミジンヌクレオチド合成に関与するが、アミノ酸自体の尿酸値低下作用は知られていない。 On the other hand, some amino acids such as aspartic acid and glutamine are involved in purine and pyrimidine nucleotide synthesis, but the uric acid level lowering action of the amino acid itself is not known.
前述のとおり、尿酸値が高く、高尿酸血症や痛風などの疾患を有する者、あるいは当該疾患の発症リスクを有する者に対して、尿酸値を低下させる医薬品や食品を提供することが強く望まれている。
従って、本発明の課題は、優れた尿酸値低下作用を発揮し、かつ安全かつ簡便に利用できる医薬品や食品等の組成物を提供することにある。
As mentioned above, it is strongly hoped to provide pharmaceuticals and foods that lower uric acid levels to those who have high uric acid levels and have diseases such as hyperuricemia and gout, or those who are at risk of developing the diseases. It is rare.
Therefore, the subject of this invention is providing the composition, such as a pharmaceutical and foodstuff which exhibits the outstanding uric acid value fall effect | action and can be used safely and simply.
本発明者らは上記課題を解決すべく鋭意研究を重ねた結果、オロト酸にアミノ酸を併用することにより、オロト酸単独よりも有意に尿酸値を低下させることができることを見出し、本発明を完成させるに至った。 As a result of intensive studies to solve the above-mentioned problems, the present inventors have found that by using an amino acid in combination with orotic acid, the uric acid level can be significantly reduced as compared with orotic acid alone, and the present invention has been completed. I came to let you.
即ち、本発明は以下の発明を包含する。
（１）オロト酸またはその塩、およびアミノ酸を有効成分として含有する尿酸値低下用組成物。
（２）組成物中のオロト酸またはその塩とアミノ酸との割合が、重量比で、１０：１〜１：１０である請求項１に記載の組成物。
（３）オロト酸またはその塩が、オロト酸フリー体（遊離体）である、（１）または（２）に記載の組成物。
（４）アミノ酸が、アスパラギン、グルタミン、およびグルタミン酸からなる群より選ばれる少なくとも１種である、（１）〜（３）のいずれかに記載の組成物。
（５）アミノ酸がアスパラギンおよび／またはグルタミン酸である、（１）〜（３）のいずれかに記載の組成物。
（６）食品の形態で提供される、（１）〜（５）のいずれかに記載の組成物。
（７）食品が飲料の形態である、（６）に記載の組成物。
（８）食品が、健康食品、機能性食品、特定保健用食品、栄養補助食品、または病者用食品である、（７）に記載の組成物。
（９）医薬品の形態で提供される、（１）〜（５）のいずれかに記載の組成物。
（１０）尿酸値低下により病態が改善される疾患の治療または予防に用いられる、（１）〜（９）のいずれかに記載の組成物。
(１１）尿酸値低下により病態が改善される疾患が、痛風、高尿酸血症、痛風結節、尿路結石、腎不全、痛風腎、前立腺肥大、および浮腫からなる群から選択される、（１０）に記載の組成物。
(１２)尿酸値を低下させるための食品または医薬品の製造における、（１）〜（１１）に記載の組成物の使用。
That is, the present invention includes the following inventions.
(1) A composition for lowering uric acid level, containing orotic acid or a salt thereof and an amino acid as active ingredients.
(2) The composition according to claim 1, wherein the ratio of orotic acid or a salt thereof and the amino acid in the composition is 10: 1 to 1:10 by weight.
(3) The composition according to (1) or (2), wherein orotic acid or a salt thereof is an orotic acid free form (free form).
(4) The composition according to any one of (1) to (3), wherein the amino acid is at least one selected from the group consisting of asparagine, glutamine, and glutamic acid.
(5) The composition according to any one of (1) to (3), wherein the amino acid is asparagine and / or glutamic acid.
(6) The composition according to any one of (1) to (5), which is provided in the form of food.
(7) The composition according to (6), wherein the food is in the form of a beverage.
(8) The composition according to (7), wherein the food is a health food, a functional food, a food for specified health use, a dietary supplement, or a food for a sick person.
(9) The composition according to any one of (1) to (5), which is provided in the form of a pharmaceutical product.
(10) The composition according to any one of (1) to (9), which is used for treatment or prevention of a disease whose pathological condition is improved by a decrease in uric acid level.
(11) The disease whose pathological condition is improved by lowering the uric acid level is selected from the group consisting of gout, hyperuricemia, gout nodules, urolithiasis, renal failure, gout kidney, prostatic hypertrophy, and edema (10 ).
(12) Use of the composition according to any one of (1) to (11) in the manufacture of a food or pharmaceutical product for lowering the uric acid level.
本発明によれば、優れた尿酸値低下作用を有する組成物が提供される。本発明の組成物の尿酸値低下成分であるオロト酸およびアミノ酸は、安全性に優れ、長期に摂取しても副作用がない。従って、本発明の尿酸値低下用組成物は、高尿酸血症や通風の治療および予防に有用である。 According to the present invention, a composition having an excellent uric acid level lowering effect is provided. The orotic acid and amino acid, which are components for lowering the uric acid level of the composition of the present invention, are excellent in safety and have no side effects even when taken for a long time. Therefore, the composition for decreasing uric acid level of the present invention is useful for the treatment and prevention of hyperuricemia and ventilation.
本発明の尿酸値低下用組成物は、有効成分として、(i) オロト酸またはその塩、および(ii) アミノ酸の２成分を含有する。オロト酸またはその塩と、アミノ酸は相乗的に作用して、優れた尿酸値低下作用を奏する。 The uric acid level-decreasing composition of the present invention contains two components of (i) orotic acid or a salt thereof and (ii) an amino acid as active ingredients. Orotic acid or a salt thereof and an amino acid act synergistically to produce an excellent uric acid level lowering effect.
本願明細書において「尿酸値の低下」とは、正常な血清尿酸値を超える値となった尿酸値を下げること、好ましくは、正常な値以下に下げることを意味する。正常な値血清尿酸値は、７ｍｇ／ｄｌ以下である。血清尿酸値が降下したか否かは、血清中の尿酸値を測定することにより確認することができる。 In the present specification, “decrease in uric acid level” means to lower the uric acid level that exceeds the normal serum uric acid level, preferably to lower than the normal level. Normal value Serum uric acid level is 7 mg / dl or less. Whether or not the serum uric acid level has decreased can be confirmed by measuring the uric acid level in the serum.
本発明において、オロト酸とはウラシル−４−カルボン酸を表し、オロト酸またはその塩は、微生物由来のもの、化学合成により得られるもの、市販のもの、乳清等食品から抽出したもの等のいずれを用いてもよい。微生物由来のオロト酸としては、例えばUS5,013,656記載の製造方法により取得されるオロト酸等が挙げられる。 In the present invention, orotic acid represents uracil-4-carboxylic acid, and orotic acid or a salt thereof is derived from microorganisms, obtained by chemical synthesis, commercially available, extracted from foods such as whey, etc. Any of them may be used. Examples of microorganism-derived orotic acid include orotic acid obtained by the production method described in US Pat. No. 5,013,656.
オロト酸またはその塩としては、オロト酸フリー体（遊離体）やオロト酸の塩が挙げられるが、オロト酸フリー体（遊離体）が好ましい。 Examples of orotic acid or salts thereof include orotic acid free form (free form) and orotic acid salts, and orotic acid free form (free form) is preferred.
オロト酸の塩としては、例えば酸付加塩、金属塩、アンモニウム塩、有機アミン付加塩、アミノ酸付加塩等が挙げられる。酸付加塩としては、塩酸塩、硫酸塩、硝酸塩、リン酸塩等の無機酸塩、酢酸塩、マレイン酸塩、フマル酸塩、クエン酸塩、リンゴ酸塩、乳酸塩、α−ケトグルタル酸塩、グルコン酸塩、カプリル酸塩等の有機酸塩が挙げられる。金属塩としては、ナトリウム塩、カリウム塩等のアルカリ金属塩、マグネシウム塩、カルシウム塩等のアルカリ土類金属塩、アルミニウム塩、亜鉛塩等が挙げられる。アンモニウム塩としては、アンモニウム、テトラメチルアンモニウム等の塩が挙げられる。有機アミン付加塩としては、モルホリン、ピペリジン等の塩が挙げられる。アミノ酸付加塩としては、グリシン、フェニルアラニン、リジン、アスパラギン酸、グルタミン酸等の塩があげられ、アスパラギン酸、グルタミン酸等の塩または２つの塩を適宜組み合わせて用いるのが好ましい。 Examples of orotic acid salts include acid addition salts, metal salts, ammonium salts, organic amine addition salts, amino acid addition salts, and the like. Acid addition salts include inorganic acid salts such as hydrochloride, sulfate, nitrate, phosphate, acetate, maleate, fumarate, citrate, malate, lactate, α-ketoglutarate , Organic acid salts such as gluconate and caprylate. Examples of the metal salt include alkali metal salts such as sodium salt and potassium salt, alkaline earth metal salts such as magnesium salt and calcium salt, aluminum salt and zinc salt. Examples of ammonium salts include salts such as ammonium and tetramethylammonium. Examples of the organic amine addition salt include salts of morpholine, piperidine and the like. Examples of amino acid addition salts include salts of glycine, phenylalanine, lysine, aspartic acid, glutamic acid and the like, and it is preferable to use a salt of aspartic acid, glutamic acid or the like or a combination of two salts as appropriate.
本発明において用いられるアミノ酸としては、オロト酸との併用により尿酸値低下作用を有するものであれば限定はされないが、例えば、アラニン、アルギニン、アスパラギン、アスパラギン酸、システイン、グルタミン、グルタミン酸、 グリシン、ヒスチジン、イソロイシン、ロイシン、リジン、メチオニン、フェニルアラニン、プロリン、セリン、トレオニン、トリプトファン、チロシン、バリンなどが挙げられる。これらのアミノ酸のなかでも、アスパラギン酸、アスパラギン、グルタミン酸、グルタミンが好ましく、アスパラギン、グルタミン酸、グルタミンがより好ましく、アスパラギン、グルタミン酸が最も好ましい。また、上記アミノ酸は、１種でもよく、２種以上の組み合わせであってもよい。 The amino acid used in the present invention is not limited as long as it has a uric acid level lowering action in combination with orotic acid. For example, alanine, arginine, asparagine, aspartic acid, cysteine, glutamine, glutamic acid, glycine, histidine , Isoleucine, leucine, lysine, methionine, phenylalanine, proline, serine, threonine, tryptophan, tyrosine, valine and the like. Among these amino acids, aspartic acid, asparagine, glutamic acid and glutamine are preferable, asparagine, glutamic acid and glutamine are more preferable, and asparagine and glutamic acid are most preferable. Further, the amino acid may be one kind or a combination of two or more kinds.
本発明の尿酸値低下用組成物中の、オロト酸またはその塩とアミノ酸との割合は、重量比で１：１００〜１００：１、好ましくは１：５０〜５０：１、より好ましくは１０：１〜１：１０である。 The ratio of orotic acid or a salt thereof and amino acid in the composition for lowering uric acid level of the present invention is 1: 100 to 100: 1, preferably 1:50 to 50: 1, more preferably 10: by weight. 1-1: 10.
本発明の尿酸値低下用組成物としては、オロト酸またはその塩、およびアミノ酸をそのまま投与することも可能であるが、本発明の効果を損なわない範囲で適宜他の成分を配合し、食品や医薬品等の各種組成物として提供することが好ましい。 As the uric acid level-decreasing composition of the present invention, orotic acid or a salt thereof and an amino acid can be administered as they are, but other ingredients are appropriately blended within a range not impairing the effects of the present invention, It is preferably provided as various compositions such as pharmaceuticals.
本発明の食品は、オロト酸またはその塩とアミノ酸を有効量含有した食品である。ここで「有効量含有した」とは、個々の食品において通常喫食される量を摂取した場合に、後述するような範囲で有効成分が摂取されるような含有量をいう。 The food of the present invention is a food containing effective amounts of orotic acid or a salt thereof and an amino acid. Here, “contained in an effective amount” refers to a content in which an active ingredient is ingested in a range as described later when an amount normally consumed in each food is ingested.
本発明の食品の形態は、飲料の形態であってもよい。また、食品の形状は、哺乳動物が摂取可能であり、かつ食用に適した形状であれば特に制限はないが、例えば、固形状、液状、半液体状、顆粒状、粒状、粉末状、カプセル状、クリーム状、ペースト状が挙げられる。 The form of the food of the present invention may be in the form of a beverage. The shape of the food is not particularly limited as long as it can be ingested by mammals and is suitable for food. For example, solid, liquid, semi-liquid, granular, granular, powder, capsule , Cream, and paste.
本発明の食品には、オロト酸またはその塩とアミノ酸を単独で配合してもよいが、通常は、各食品の形態に応じた他の成分とともに配合する。 In the food of the present invention, orotic acid or a salt thereof and an amino acid may be blended alone, but they are usually blended together with other components according to the form of each food.
他の成分としては、本発明の効果を損なわない範囲のものであれば特に限定はされず、例えば、各種タンパク質、糖類、脂肪、微量元素、ビタミン類、クエン酸や酢酸等の有機酸塩等が挙げられる。また、本発明の食品は、その種類に応じて食品において許容され、通常使用される添加剤、例えば、アスパルテーム、ステビア等の甘味料、クエン酸、リンゴ酸、酒石酸等の酸味料、デキストリン、澱粉等の賦形剤のほか、着色料、香料、苦味料、緩衝剤、増粘安定剤、ゲル化剤、安定剤、ガムベース、結合剤、希釈剤、乳化剤、分散剤、懸濁化剤、酸化防止剤、保存料、防腐剤、防かび剤、発色剤、漂白剤、光沢剤、酵素、調味料、香辛料抽出物等などを適宜添加してもよい。 Other components are not particularly limited as long as they do not impair the effects of the present invention. Examples include various proteins, sugars, fats, trace elements, vitamins, organic acid salts such as citric acid and acetic acid, etc. Is mentioned. Further, the food of the present invention is acceptable in food depending on its type, and commonly used additives, for example, sweeteners such as aspartame and stevia, acidulants such as citric acid, malic acid and tartaric acid, dextrin and starch In addition to such excipients, coloring agents, flavoring agents, bittering agents, buffering agents, thickening stabilizers, gelling agents, stabilizers, gum bases, binders, diluents, emulsifiers, dispersants, suspending agents, oxidation agents Inhibitors, preservatives, preservatives, fungicides, color formers, bleaches, brighteners, enzymes, seasonings, spice extracts and the like may be added as appropriate.
また、オロト酸またはその塩とアミノ酸を発酵食品の素材として用いることができる。より具体的には、本発明の食品は、オロト酸またはその塩とアミノ酸に酵母、乳酸菌、麹菌などの微生物が発酵するために必要なグルコースなどの糖源や酵母エキスなどの栄養源を添加して発酵させる発酵食品であってもよい。 Orotic acid or a salt thereof and an amino acid can be used as a material for fermented foods. More specifically, in the food of the present invention, a sugar source such as glucose and a nutrient source such as yeast extract necessary for fermentation of microorganisms such as yeast, lactic acid bacteria, and koji molds are added to orotic acid or a salt thereof and an amino acid. It may be a fermented food to be fermented.
本発明において「食品」とは、健康食品、機能性食品、特定保健用食品、栄養補助食品、病者用食品を含む意味で用いられる。なかでも、尿酸値降下機能を期待する消費者に適した食品、すなわち特定保健用食品として提供することが好適である。ここでいう「特定保健用食品」とは、高尿酸血症や痛風の改善等を目的として食品の製造または販売等を行う場合に、保健上の観点から法上の何らかの制限を受けることがある食品をいう。 In the present invention, “food” is used in the meaning including health food, functional food, food for specified health use, dietary supplement, and food for the sick. Especially, it is suitable to provide as a food suitable for consumers who expect a uric acid level lowering function, that is, a food for specified health use. The “special health foods” referred to here may be subject to some legal restrictions from the viewpoint of health when manufacturing or selling foods for the purpose of improving hyperuricemia or gout. Refers to food.
上記健康食品等は、通常の食品の形状であってもよいが、好ましくは、サプリメントの形状（錠剤、顆粒剤、細粒剤、タブレット、チュアブルタブレット、カプセル（軟カプセル、硬カプセル）など）であることが好ましい。 The health food and the like may be in the form of a normal food, but preferably in the form of a supplement (tablets, granules, fine granules, tablets, chewable tablets, capsules (soft capsules, hard capsules, etc.)). Preferably there is.
本発明において、オロト酸またはその塩とアミノ酸の配合の対象となる食品としては、清涼飲料、炭酸飲料、栄養飲料、果実飲料、乳飲料などの飲料（これらの飲料の濃縮原液及び調整用粉末を含む)；飯類、麺類、パン類、およびパスタ類などの炭水化物含有飲食；クッキーやケーキなどの洋菓子類、饅頭や羊羹などの和菓子類、キャンディー類、ガム類、ヨーグルト、プリン、ゼリーなどの冷菓や氷菓などの各種菓子類；かまぼこ、ちくわ、ハンバーグ、ハム、ソーセージ等の水産・畜産加工食品；加工乳、発酵乳、ヨーグルト、バター、チーズ等の乳製品；マーガリン、マヨネーズ、ショートニング、ホイップクリーム、ドレッシング等の油脂及び油脂加工食品；ソース、たれ等の調味料などを例示することができるが、これらに限定はされない。 In the present invention, foods to be combined with orotic acid or a salt thereof and amino acids include beverages such as soft drinks, carbonated drinks, nutritional drinks, fruit drinks, and milk drinks (concentrated concentrates of these drinks and adjustment powders). Including carbohydrates such as rice, noodles, bread, and pasta; Western confectionery such as cookies and cakes; Japanese confectionery such as buns and sheep candy; and frozen confectionery such as candy, gums, yogurt, pudding, and jelly Confectionery such as kamaboko, chikuwa, hamburger, ham, sausage, etc .; dairy products such as processed milk, fermented milk, yogurt, butter, cheese; margarine, mayonnaise, shortening, whipped cream, Fats and oils and fat processed foods such as dressings; seasonings such as sauces and sauces can be exemplified, but the limitations are Not.
本発明の食品のより好ましい態様としては、飲料（例えば、茶飲料、ビール系飲料、コーヒー、ミネラルウォーター、乳飲料）やヨーグルトが挙げられる。 More preferable embodiments of the food of the present invention include beverages (for example, tea beverages, beer-based beverages, coffee, mineral water, milk beverages) and yogurt.
ここで、茶飲料とは、ツバキ科の常緑樹である茶樹の葉（茶葉）、または茶樹以外の植物の葉もしくは穀類等を煎じて飲むための飲料をいい、発酵茶、半発酵茶、および不発酵茶のいずれもが包含される。茶飲料の具体例としては、日本茶（例えば、緑茶、麦茶）、紅茶、ハーブ茶（例えば、ジャスミン茶）、中国茶（例えば、中国緑茶、烏龍茶）、ほうじ茶等が挙げられる。 Here, tea beverages refer to beverages for decocting and drinking tea leaves (tea leaves), which are evergreen trees of the camellia family, or leaves or grains of plants other than tea trees, such as fermented tea, semi-fermented tea, and non-fermented tea. Any fermented tea is included. Specific examples of tea beverages include Japanese tea (for example, green tea, barley tea), black tea, herbal tea (for example, jasmine tea), Chinese tea (for example, Chinese green tea, oolong tea), hoji tea, and the like.
ビール系飲料は、ビール、発泡酒、第３のビール及びアルコール不含のビール風炭酸飲料等が挙げられる。ミネラルウォーターは、発泡性及び非発泡性のミネラルウォーターが挙げられる。 Examples of the beer-based beverage include beer, happoshu, third beer, and alcohol-free beer-style carbonated beverages. Examples of the mineral water include foaming and non-foaming mineral water.
乳飲料とは、生乳、牛乳等またはこれらを原料として製造した食品を主原料とした飲料をいい、牛乳等そのもの材料とするものの他に、例えば、栄養素強化乳、フレーバー添加乳、加糖分解乳等の加工乳を原料とするものも包含される。 Milk beverages refer to beverages made mainly from raw milk, milk, etc. or foods made from these raw materials. In addition to those made of milk and other ingredients, for example, nutrient-enriched milk, flavored milk, and sugar-decomposed milk Those made from processed milk are also included.
またヨーグルトには、ハードタイプ、ソフトタイプ、ドリンクタイプのいずれのものも包含され、さらにヨーグルトを原料とする加工ヨーグルト製品も包含される。 The yogurt includes any of a hard type, a soft type, and a drink type, and further includes a processed yogurt product using yogurt as a raw material.
本発明において提供される飲料（飲料形態の健康食品や機能性食品を含む）の製造に当たっては、通常の飲料の処方設計に用いられている糖類、香料、果汁、食品添加剤などを適宜添加することができる。飲料の製造に当たってはまた、当業界に公知の製造技術を参照することができ、例えば、「改訂新版ソフトドリンクス」（株式会社光琳）を参考とすることができる。 In the production of beverages (including health foods and functional foods in the form of beverages) provided in the present invention, sugars, fragrances, fruit juices, food additives, etc. used for normal beverage formulation design are added as appropriate. be able to. In the production of beverages, production techniques known in the art can also be referred to, for example, “Revised New Version Soft Drinks” (Kokai Co., Ltd.) can be referred to.
本発明の尿酸値低下用組成物中の有効成分であるオロト酸またはその塩とアミノ酸の配合量は、当該組成物の種類や当該組成物の投与により期待する効果等に応じて適宜選択されるが、有効成分合計量が通常０．０００１〜１００重量％、好ましくは０．００１〜７０重量％、特に好ましくは０．０１〜５０重量％である。 The blending amount of orotic acid or its salt and amino acid, which is an active ingredient in the composition for decreasing uric acid level of the present invention, is appropriately selected according to the type of the composition, the effect expected by administration of the composition, and the like. However, the total amount of active ingredients is usually 0.0001 to 100% by weight, preferably 0.001 to 70% by weight, and particularly preferably 0.01 to 50% by weight.
本発明の尿酸値低下用組成物を例えば飲食品の形態で提供する場合、飲食品への有効成分の配合量は、その尿酸値低下作用が発揮できる量であればよいが、対象飲食品の一般的な摂取量を考慮して、通常、成人１日当たりの摂取量が、オロト酸またはその塩、およびアミノ酸の合計として、１ｍｇ〜１０ｇ、好ましくは５ｍｇ〜５ｇ、より好ましくは１０ｍｇ〜１ｇとなる量とすればよい。 When the composition for lowering uric acid level of the present invention is provided, for example, in the form of food or drink, the compounding amount of the active ingredient in the food or drink may be an amount that can exert the action of lowering the uric acid level. In consideration of general intake, the daily intake for adults is usually 1 mg to 10 g, preferably 5 mg to 5 g, more preferably 10 mg to 1 g as the sum of orotic acid or a salt thereof and amino acids. It can be an amount.
本発明の食品は、例えば、生活習慣、体質、または遺伝などの要素によって尿酸値の高い傾向のある人はもとより、正常人であっても、痛風や高尿酸血症の予防または改善を目的として日常的に摂取することができる。 The food of the present invention is used for the purpose of preventing or improving gout and hyperuricemia, not only for people who tend to have high uric acid levels due to factors such as lifestyle, constitution, or heredity, but also for normal people. Can be taken on a daily basis.
また、本発明の組成物を医薬品として提供する場合は、オロト酸またはその塩とアミノ酸はそのままで、または医薬上許容され、かつ剤型に応じて適宜選択した適当な添加剤（例えば担体、賦形剤、希釈剤、結合剤、滑沢剤、崩壊剤又は崩壊補助剤、可溶化剤、安定化剤、保存剤、防腐剤、増量剤、増粘剤、乳化剤、分散剤、懸濁化剤、緩衝剤等）を用いて、公知の種々の方法にて経口又は非経口的に全身又は局所投与することができる各種製剤形態に調製すればよい。 When the composition of the present invention is provided as a pharmaceutical product, orotic acid or a salt thereof and an amino acid are used as they are or are pharmaceutically acceptable and appropriately selected according to the dosage form (for example, a carrier, an excipient). Forms, diluents, binders, lubricants, disintegrants or disintegrants, solubilizers, stabilizers, preservatives, preservatives, extenders, thickeners, emulsifiers, dispersants, suspending agents And various other preparations that can be systemically or locally administered by various known methods orally or parenterally.
本発明の医薬は、経口または非経口的に投与することができるが、好ましくは経口投与である。本発明の医薬を経口投与する場合は、錠剤（糖衣錠を含む）、カプセル剤、顆粒剤、散剤、丸剤、内用水剤、懸濁剤、乳剤、シロップ剤等に製剤化するか、使用する際に再溶解させる乾燥生成物にしてもよい。また、本発明の医薬を非経口投与する場合は、注射剤（例えば、皮下注射剤、静脈内注射剤、筋肉内注射剤、腹腔内注射剤）、点滴剤、坐剤（例えば、直腸坐剤、膣坐剤）などに製剤化し、注射用製剤の場合は単位投与量アンプル又は多投与量容器の状態で提供される。 The medicament of the present invention can be administered orally or parenterally, but is preferably administered orally. When orally administering the medicament of the present invention, it is formulated or used in tablets (including sugar-coated tablets), capsules, granules, powders, pills, liquids for internal use, suspensions, emulsions, syrups, etc. You may make it the dried product re-dissolved in the case. In addition, when the medicament of the present invention is administered parenterally, an injection (eg, subcutaneous injection, intravenous injection, intramuscular injection, intraperitoneal injection), instillation, suppository (eg, rectal suppository) , Vaginal suppositories, etc., and in the case of injectable preparations, they are provided in the form of unit dose ampoules or multi-dose containers.
製剤は、例えば下記のようにして製造できる。経口剤は、有効成分に、賦形剤（例えば、乳糖、白糖、デンプン、マンニトール）、崩壊剤（例えば、炭酸カルシウム、カルボキシメチルセルロースカルシウム）、結合剤（例えば、α化デンプン、アラビアゴム、カルボキシメチルセルロース、ポリビニールピロリドン、ヒドロキシプロピルセルロース）、滑沢剤（例えば、タルク、ステアリン酸マグネシウム、ポリエチレングリコール６０００）を添加して圧縮成形し、次いで必要により、味のマスキング、腸溶性あるいは持続性の目的のため自体公知の方法でコーティングすることにより製造することができる。コーティング剤としては、例えばエチルセルロース、ヒドロキシメチルセルロース、ポリオキシエチレングリコール、セルロースアセテートフタレート、ヒドロキシプロピルメチルセルロースフタレートおよびオイドラギット（ローム社製、ドイツ、メタアクリル酸・アクリル酸共重合物）などを用いることができる。 The preparation can be produced, for example, as follows. Oral preparations contain active ingredients, excipients (eg, lactose, sucrose, starch, mannitol), disintegrants (eg, calcium carbonate, carboxymethylcellulose calcium), binders (eg, pregelatinized starch, gum arabic, carboxymethylcellulose) , Polyvinyl pyrrolidone, hydroxypropyl cellulose), lubricant (eg, talc, magnesium stearate, polyethylene glycol 6000) and compression molding, then, if necessary, for taste masking, enteric or sustained purposes Therefore, it can be produced by coating by a method known per se. As the coating agent, for example, ethyl cellulose, hydroxymethyl cellulose, polyoxyethylene glycol, cellulose acetate phthalate, hydroxypropyl methylcellulose phthalate and Eudragit (Rohm, Germany, methacrylic acid / acrylic acid copolymer) can be used.
注射剤は、有効成分を分散剤（例えば、ツイーン（Ｔｗｅｅｎ）８０（アトラスパウダー社製、米国）、ＨＣＯ ６０（日光ケミカルズ製）、ポリエチレングリコール、カルボキシメチルセルロース、アルギン酸ナトリウムなど）、保存剤（例えば、メチルパラベン、プロピルパラベン、ベンジルアルコール、クロロブタノール、フェノール）、等張化剤（例えば、塩化ナトリウム、グリセリン、ソルビトール、ブドウ糖、転化糖）などと共に水性溶剤（例えば、蒸留水、生理的食塩水、リンゲル液等）あるいは油性溶剤（例えば、オリーブ油、ゴマ油、綿実油、コーン油などの植物油、プロピレングリコール）などに溶解、懸濁、または乳化することにより製造することができる。この際、所望により溶解補助剤（例えば、サリチル酸ナトリウム、酢酸ナトリウム）、安定剤（例えば、ヒト血清アルブミン）、無痛化剤（例えば、塩化ベンザルコニウム、塩酸プロカイン）等の添加物を添加してもよい。 The injection comprises an active ingredient as a dispersant (for example, Tween 80 (manufactured by Atlas Powder, USA), HCO 60 (manufactured by Nikko Chemicals), polyethylene glycol, carboxymethylcellulose, sodium alginate, etc.), preservative (for example, Methylparaben, propylparaben, benzyl alcohol, chlorobutanol, phenol), isotonic agents (for example, sodium chloride, glycerin, sorbitol, glucose, invert sugar) and aqueous solvents (for example, distilled water, physiological saline, Ringer's solution, etc.) ) Or oily solvents (for example, olive oil, sesame oil, cottonseed oil, vegetable oils such as corn oil, propylene glycol) and the like. At this time, if desired, additives such as a solubilizing agent (for example, sodium salicylate, sodium acetate), a stabilizer (for example, human serum albumin), a soothing agent (for example, benzalkonium chloride, procaine hydrochloride) are added. Also good.
製剤化に当たっては、本発明による有効成分以外の１種以上の有効成分を更に配合してもよい。また本発明による有効成分の投与に当たっては、本発明による有効成分以外の１種またはそれ以上の医療上有効な有効成分を組み合わせて投与してもよい。 In formulating, one or more active ingredients other than the active ingredient according to the present invention may be further blended. In the administration of the active ingredient according to the present invention, one or more medically effective active ingredients other than the active ingredient according to the present invention may be administered in combination.
本発明の医薬は、尿酸値低下によって病態が改善される疾患の予防及び／又は治療用医薬として用いることができる。かかる疾患としては、例えば、痛風、高尿酸血症、痛風結節、尿路結石（腎結石、尿管結石、膀胱結石）、腎不全、痛風腎、前立腺肥大、および浮腫などが挙げられるが、これらに限定はされない。本発明の医薬は上記疾患の発症を抑制する予防薬として、及び／又は、正常な状態に改善する治療薬として機能する。 The medicament of the present invention can be used as a medicament for preventing and / or treating a disease whose pathological condition is improved by lowering the uric acid level. Such diseases include, for example, gout, hyperuricemia, gout nodules, urinary calculi (renal stones, ureteral stones, bladder stones), renal failure, gout kidneys, prostatic hypertrophy, and edema. It is not limited to. The medicament of the present invention functions as a prophylactic agent that suppresses the onset of the above diseases and / or as a therapeutic agent that improves the normal state.
本発明の医薬は、前述の疾患の予防及び／又は治療用医薬として用いる場合、ヒト、マウス、ラット、ウサギ、イヌ、ネコ等の哺乳動物に対して経口または非経口的に安全に投与することができる。本発明の医薬の投与量は、疾患の種類、投与対象の年齢、性別、体重、症状の程度、又は投与方法などに応じて適宜決定することができる。例えば、痛風や高尿酸血症患者に経口投与する場合には、成人一日当り、オロト酸またはその塩、およびアミノ酸の合計として通常は１０ｍｇ〜３０ｇ、好ましくは５０ｍｇ〜１０ｇ、より好ましくは１００ｍｇ〜３ｇとなるように一日一回ないし数回投与する。投与期間は、特に限定されないが、通常は１日間〜１年間、好ましくは１週間〜３ヶ月間である。 When the medicament of the present invention is used as a medicament for the prevention and / or treatment of the aforementioned diseases, it should be safely administered orally or parenterally to mammals such as humans, mice, rats, rabbits, dogs, cats and the like. Can do. The dosage of the medicament of the present invention can be appropriately determined according to the type of disease, age, sex, body weight, symptom level, or administration method of the subject. For example, when orally administered to patients with gout and hyperuricemia, the total of orotic acid or a salt thereof and amino acids is usually 10 mg to 30 g, preferably 50 mg to 10 g, more preferably 100 mg to 3 g per day for an adult. Administer once or several times a day. The administration period is not particularly limited, but is usually 1 day to 1 year, preferably 1 week to 3 months.
以下、実施例によって本発明を更に具体的に説明するが、これらの実施例は本発明を限定するものでない。 EXAMPLES Hereinafter, the present invention will be described more specifically with reference to examples, but these examples do not limit the present invention.
（実施例１）ラットにおけるオロト酸とアミノ酸の尿酸値降下作用
被験物質としてオロト酸とアミノ酸を用い、その組み合わせによる尿酸値低下効果を調べた。
１．実験条件
６週齢の雄ＳＤラットを日本チャールスリバー社より購入し、３日間馴化後、コントロール群(ｎ＝８、ＡＩＮ９３Ｇと表記）、オロト酸１％投与群（ｎ＝８、１％オロト酸と表記）、オロト酸１％＋０．７６％アスパラギン酸投与群（ｎ＝８、０．７６％Ａｓｐと表記）、オロト酸１％＋０．７６％アスパラギン投与群（ｎ＝８、０．７６％Ａｓｎと表記）、オロト酸１％＋０．８４％グルタミン酸投与群（ｎ＝８、０．８４％Ｇｌｕと表記）、オロト酸１％＋０．８４％グルタミン投与群（ｎ＝８、０．８４％Ｇｌｎと表記）の６群に群分けし、１０日間飼育した。各被験物質は、上記記載の混餌比率により、自由摂取させた。餌組成は、下記表１に示したが、各被験物質の添加量はセルロースで置換した。１０日間飼育後、非絶食下で解剖を行い、血液及び肝臓を採取した。
(Example 1) Lowering effect of orotic acid and amino acid in rats in rats Using orotic acid and an amino acid as test substances, the effect of lowering the uric acid level by the combination was examined.
1. Experimental conditions Six-week-old male SD rats were purchased from Charles River Japan, and acclimated for 3 days, then a control group (n = 8, indicated as AIN93G), a 1% orotic acid administration group (n = 8, 1% orotic acid) ), Orotic acid 1% + 0.76% aspartic acid administration group (denoted as n = 8, 0.76% Asp), orotic acid 1% + 0.76% asparagine administration group (n = 8, 0.76%) Ast), orotic acid 1% + 0.84% glutamic acid administration group (n = 8, 0.84% Glu), orotic acid 1% + 0.84% glutamine administration group (n = 8, 0.84% The groups were divided into 6 groups (indicated as Gln) and reared for 10 days. Each test substance was ingested freely according to the above-mentioned feed ratio. The bait composition is shown in Table 1 below, but the addition amount of each test substance was replaced with cellulose. After rearing for 10 days, dissection was performed under non-fasting conditions, and blood and liver were collected.
２．測定項目
血中尿酸値と血中アラントインの分析については、採取した血漿を水で１０倍に希釈し、分子量１００００カットの遠心フィルター（アミコン、ミリポア社製）を６０００回転、９０分の遠心分離により通したものを検液として、高速液体クロマトグラフィー（ＨＰＬＣ）により測定した。
2. Measurement items For analysis of blood uric acid level and blood allantoin, the collected plasma was diluted 10-fold with water, and a centrifugal filter (Amicon, manufactured by Millipore) with a molecular weight of 10,000 was centrifuged at 6000 rpm for 90 minutes. The passed sample was used as a test solution and measured by high performance liquid chromatography (HPLC).
ＨＰＬＣは以下の条件により実施した。
ＨＰＬＣシステム：ＳＨＩＭＡＤＺＵ ＬＣｓｏｌｕｔｉｏｎ Ｓｙｓｔｅｍ（島津製作所社製）
カラム：Ｃａｄｅｎｚａ ＣＤ−Ｃ１８ １５０Ｘ４．６ｍｍ
検出：尿酸：ＵＶ２８４ｎｍ、アラントイン：ＵＶ２１０ｎｍ
移動相Ａ: ２０ｍＭリン酸バッファー(pH ４．０)
移動相Ｂ: メタノール
タイムプログラム
0-9min A: 0.495mL/min B: 0.005ml/min
9-11min A: 0.495ml/min→0.25ml/min B: 0.005ml/min→0.25ml/min
11-13min A: 0.25mL/min B: 0.25mL/min
13-15min A: 0.25ml/min→0.495ml/min B: 0.25ml/min→0.005ml/min
15-25min A: 0.495mL/min B: 0.005ml/min
注入量：１０μｌ
カラムオーブン：４０℃
流速:０．５mL/min
HPLC was performed under the following conditions.
HPLC system: SHIMADZU LCsolution System (manufactured by Shimadzu Corporation)
Column: Cadenza CD-C18 150X4.6mm
Detection: Uric acid: UV 284 nm, Allantoin: UV 210 nm
Mobile phase A: 20 mM phosphate buffer (pH 4.0)
Mobile phase B: Methanol time program
0-9min A: 0.495mL / min B: 0.005ml / min
9-11min A: 0.495ml / min → 0.25ml / min B: 0.005ml / min → 0.25ml / min
11-13min A: 0.25mL / min B: 0.25mL / min
13-15min A: 0.25ml / min → 0.495ml / min B: 0.25ml / min → 0.005ml / min
15-25min A: 0.495mL / min B: 0.005ml / min
Injection volume: 10 μl
Column oven: 40 ° C
Flow rate: 0.5mL / min
３．結果
血中尿酸値の測定結果を図１に示す。１％オロト酸摂取により、尿酸値の低下傾向が示されたが、有意ではなかった。１％オロト酸にアミノ酸を併用投与した０．７６％Ａｓｎ群、０．８４％Ｇｌｕ群、０．８４％Ｇｌｎ群においては、コントロール群（ＡＩＮ９３Ｇ)に対して尿酸値が有意に低下した。特に、０．７６％Ａｓｎ群、０．８４％Ｇｌｕ群においては、１％オロト酸単独投与群に対して尿酸値が有意に低下した。以上から、アスパラギン、グルタミン酸、グルタミンはオロト酸と併用することにより、尿酸低下作用が認められ、特に、アスパラギン、グルタミン酸は、オロト酸の尿酸低下作用の増強効果が高いことが示された。
3. Results The measurement results of blood uric acid levels are shown in FIG. 1% orotic acid intake showed a tendency to decrease uric acid levels, but was not significant. In the 0.76% Asn group, 0.84% Glu group, and 0.84% Gln group in which amino acids were co-administered with 1% orotic acid, the uric acid level was significantly lower than that in the control group (AIN93G). In particular, in the 0.76% Asn group and the 0.84% Glu group, the uric acid level significantly decreased compared to the 1% orotic acid alone administration group. From the above, it was shown that asparagine, glutamic acid and glutamine have a uric acid lowering action when used in combination with orotic acid, and in particular, asparagine and glutamic acid have a high enhancing effect on the uric acid lowering action of orotic acid.
血中アラントイン値の測定結果を図２に示す。１％オロト酸摂取により、血中アラントイン値の低下傾向が示されたが、有意ではなかった。１％オロト酸にアミノ酸を併用投与した０．７６％Ａｓｐ群、０．７６％Ａｓｎ群、０．８４％Ｇｌｕ群、０．８４％Ｇｌｎ群においては、コントロール群（ＡＩＮ９３Ｇ)に対して血中アラントイン値が有意に低下した。特に、０．７６％Ａｓｎ群、０．８４％Ｇｌｕ群、０．８４％Ｇｌｎ群においては、１％オロト酸単独投与群に対して血中アラントイン値が有意に低下した。以上から、アスパラギン酸、アスパラギン、グルタミン酸、グルタミンはオロト酸と併用することにより、いずれも血中アラントイン低下作用が認められ、特に、アスパラギン、グルタミン酸、グルタミンは、オロト酸の血中アラントイン低下作用の増強効果が高いことが示された。 The measurement result of the blood allantoin value is shown in FIG. The intake of 1% orotic acid showed a tendency to decrease the blood allantoin level, but it was not significant. In the 0.76% Asp group, 0.76% Asn group, 0.84% Glu group, and 0.84% Gln group in which amino acids were co-administered with 1% orotic acid, the blood level was higher than that in the control group (AIN93G). Allantoin levels were significantly reduced. In particular, in the 0.76% Asn group, the 0.84% Glu group, and the 0.84% Gln group, the blood allantoin value significantly decreased compared to the 1% orotic acid alone administration group. From the above, aspartic acid, asparagine, glutamic acid, and glutamine all showed a blood allantoin lowering effect when used in combination with orotic acid, and in particular, asparagine, glutamic acid, and glutamine enhanced the blood allantoin lowering action of orotic acid. It was shown that the effect is high.
アラントインはげっ歯動物におけるプリン体の最終代謝産物であり、血中尿酸低下作用及び血中アラントイン低下作用両方において、オロト酸とアミノ酸を組み合わせによる相乗効果が確認できた。 Allantoin is the final metabolite of purines in rodents, and a synergistic effect of combining orotic acid and amino acid was confirmed in both blood uric acid lowering action and blood allantoin lowering action.
本発明は、尿酸値低下を目的とした機能性食品やサプリメントなどの飲食品や医薬品の製造分野において利用できる。 INDUSTRIAL APPLICATION This invention can be utilized in the manufacture field | area of food-drinks and pharmaceuticals, such as a functional food and a supplement aiming at the uric acid value fall.
Claims (12)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2009253183A JP2011098896A (en) | 2009-11-04 | 2009-11-04 | Composition for reducing uric acid value |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2009253183A JP2011098896A (en) | 2009-11-04 | 2009-11-04 | Composition for reducing uric acid value |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JP2011098896A true JP2011098896A (en) | 2011-05-19 |
Family
ID=44190396
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009253183A Pending JP2011098896A (en) | 2009-11-04 | 2009-11-04 | Composition for reducing uric acid value |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP2011098896A (en) |
Cited By (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013111716A1 (en) * | 2012-01-27 | 2013-08-01 | キリンホールディングス株式会社 | Sweetener composition and method for improving sweetness of sweet substance |
| WO2018012157A1 (en) | 2016-07-14 | 2018-01-18 | 昭和電工株式会社 | Melanin production inhibitor, skin-lightening agent, fibroblast cell activator, collagen and/or elastin production promotor, and wrinkle-improving agent |
| JP2018027915A (en) * | 2016-08-18 | 2018-02-22 | 国立大学法人東北大学 | Oral composition having inhibitory activity of retinal ganglion cell death |
| CN107996652A (en) * | 2017-12-27 | 2018-05-08 | 吉林农业大学 | A kind of deacidification antigout healthy biscuit and its production method |
| JP2018095590A (en) * | 2016-12-13 | 2018-06-21 | 株式会社古川リサーチオフィス | Blood uric acid value increase inhibitor and screening method of blood uric acid value increase inhibiting substance |
| CN108619126A (en) * | 2018-07-03 | 2018-10-09 | 南京中医药大学 | The medical usage of aspartic acid |
| WO2018207929A1 (en) | 2017-05-12 | 2018-11-15 | 株式会社古川リサーチオフィス | Arterial oxygen saturation degree improver |
| WO2019044348A1 (en) | 2017-08-30 | 2019-03-07 | アサヒグループホールディングス株式会社 | Composition for decreasing serum uric acid level |
| WO2020091014A1 (en) | 2018-11-02 | 2020-05-07 | 株式会社古川リサーチオフィス | Heart rate decreasing agent |
| JP2021001902A (en) * | 2020-09-18 | 2021-01-07 | 株式会社古川リサーチオフィス | Evaluation method of composition suppressing increase in blood urate level |
| CN115350227A (en) * | 2022-09-22 | 2022-11-18 | 赵奎 | Traditional Chinese medicine composition for treating gout and preparation method thereof |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2003532679A (en) * | 2000-05-08 | 2003-11-05 | エヌ・ヴイ・ヌートリシア | Nutritional formulation containing ribose and folic acid and its medical use |
| JP2004517804A (en) * | 2000-06-28 | 2004-06-17 | メルク・アンド・カンパニー・インコーポレーテッド | Cardiovascular disease treatment |
-
2009
- 2009-11-04 JP JP2009253183A patent/JP2011098896A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2003532679A (en) * | 2000-05-08 | 2003-11-05 | エヌ・ヴイ・ヌートリシア | Nutritional formulation containing ribose and folic acid and its medical use |
| JP2004517804A (en) * | 2000-06-28 | 2004-06-17 | メルク・アンド・カンパニー・インコーポレーテッド | Cardiovascular disease treatment |
Non-Patent Citations (3)
| Title |
|---|
| JPN6013050309; Ｊ．ＤＡＩＲＹ ＳＣＩ． ＶＯＬ．８５, 2002, Ｐ．２１２２-２１２９ * |
| JPN6013050311; ＢＲＩＴＩＳＨ ＪＯＵＲＮＡＬ ＯＦ ＮＵＴＲＩＴＩＯＮ ＶＯＬ．９０, 2003, Ｐ．１２７-１３３ * |
| JPN6013050313; ＮＡＴＵＲＥ ＶＯＬ．４１７, 2002, Ｐ．４４７-４５２ * |
Cited By (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPWO2013111716A1 (en) * | 2012-01-27 | 2015-05-11 | キリンホールディングス株式会社 | Sweetener composition and method for improving sweetness of sweet substances |
| WO2013111716A1 (en) * | 2012-01-27 | 2013-08-01 | キリンホールディングス株式会社 | Sweetener composition and method for improving sweetness of sweet substance |
| US10646487B2 (en) | 2016-07-14 | 2020-05-12 | Showa Denko K.K. | Melanin production inhibitor, whitening agent, fibroblast activator, collagen and/or elastin production promotor and wrinkle ameliorant |
| WO2018012157A1 (en) | 2016-07-14 | 2018-01-18 | 昭和電工株式会社 | Melanin production inhibitor, skin-lightening agent, fibroblast cell activator, collagen and/or elastin production promotor, and wrinkle-improving agent |
| US11045471B2 (en) | 2016-07-14 | 2021-06-29 | Showa Denko K.K. | Melanin production inhibitor, whitening agent, fibroblast activator, collagen and/or elastin production promotor and wrinkle ameliorant |
| JP2018027915A (en) * | 2016-08-18 | 2018-02-22 | 国立大学法人東北大学 | Oral composition having inhibitory activity of retinal ganglion cell death |
| JP2018095590A (en) * | 2016-12-13 | 2018-06-21 | 株式会社古川リサーチオフィス | Blood uric acid value increase inhibitor and screening method of blood uric acid value increase inhibiting substance |
| US11331318B2 (en) | 2017-05-12 | 2022-05-17 | Furukawa Research Office Co., Ltd. | Arterial oxygen saturation degree improver |
| CN110709086A (en) * | 2017-05-12 | 2020-01-17 | 古川研究所有限公司 | Agent for improving arterial blood oxygen saturation |
| JPWO2018207929A1 (en) * | 2017-05-12 | 2020-01-23 | 株式会社古川リサーチオフィス | Arterial blood oxygen saturation enhancer |
| WO2018207929A1 (en) | 2017-05-12 | 2018-11-15 | 株式会社古川リサーチオフィス | Arterial oxygen saturation degree improver |
| WO2019044348A1 (en) | 2017-08-30 | 2019-03-07 | アサヒグループホールディングス株式会社 | Composition for decreasing serum uric acid level |
| JP6492236B1 (en) * | 2017-08-30 | 2019-03-27 | アサヒグループホールディングス株式会社 | Composition for reducing serum uric acid level |
| US11173143B2 (en) | 2017-08-30 | 2021-11-16 | Asahi Group Holdings, Ltd. | Composition for decreasing serum uric acid level |
| CN107996652A (en) * | 2017-12-27 | 2018-05-08 | 吉林农业大学 | A kind of deacidification antigout healthy biscuit and its production method |
| CN108619126A (en) * | 2018-07-03 | 2018-10-09 | 南京中医药大学 | The medical usage of aspartic acid |
| WO2020091014A1 (en) | 2018-11-02 | 2020-05-07 | 株式会社古川リサーチオフィス | Heart rate decreasing agent |
| JP2021001902A (en) * | 2020-09-18 | 2021-01-07 | 株式会社古川リサーチオフィス | Evaluation method of composition suppressing increase in blood urate level |
| CN115350227A (en) * | 2022-09-22 | 2022-11-18 | 赵奎 | Traditional Chinese medicine composition for treating gout and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2011098896A (en) | Composition for reducing uric acid value | |
| JP2011136907A (en) | Endurance-enhancing agent | |
| JP2008255063A (en) | Composition having blood pressure elevation inhibitory activity | |
| JP5594819B2 (en) | Composition for improving lipid metabolism | |
| CA2939843C (en) | Methods and compositions for using cinnamaldehyde and zinc for weight management | |
| JP2021065226A (en) | Composition for improving cognitive function speed | |
| JP6157928B2 (en) | Fat accumulation inhibitor in the liver | |
| JP2014237715A (en) | Agent for alleviating alcoholic fatigue | |
| JP2012126683A (en) | Composition for sympathetic activation | |
| WO2019083070A1 (en) | Composition for preventing or alleviating nonalcoholic fatty liver disease | |
| CN112912070A (en) | Therapeutic or prophylactic agent for nocturnal polyuria | |
| KR101883096B1 (en) | Pharmaceutical composition for preventing or treating acute lung injury or acute respiratory distress syndrome, comprising copper peptide | |
| WO2019044348A1 (en) | Composition for decreasing serum uric acid level | |
| JP7090849B2 (en) | Liver function improving composition and liver function improving food composition | |
| JP2002255801A (en) | Composition for prophylaxis of hypertension | |
| JP6112767B2 (en) | Composition for lowering uric acid level in blood | |
| JPWO2008136173A1 (en) | Adipocyte differentiation inhibitor comprising a stilbene derivative as an active ingredient | |
| JPWO2019168149A1 (en) | Peptides that improve cognitive function | |
| JP2007269750A (en) | Composition for improving insulin resistance, composition for increasing adiponectin, composition for improving hemoglobin A1c, composition for improving blood glucose level, composition for reducing uric acid level, composition for improving liver function, composition for reducing waist circumference, and body weight Reducing action composition | |
| KR102575452B1 (en) | Microorganism strain having activity of improving liver function and use thereof | |
| JP4611775B2 (en) | Antihypertensive | |
| JP6391066B2 (en) | Ornithine-containing composition for improving body composition | |
| JP6329317B1 (en) | Blood pressure lowering composition | |
| WO2006038613A1 (en) | Oral composition containing difructose anhydride | |
| JP2006213628A (en) | Anti-stress agent |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20120530 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20131015 |
|
| A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20131212 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20140225 |